LEND: Multi-Center, Randomized, Double-Blind, 12 Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and...
Project Description:
BP28420 from Roche TCRC, Inc.2014-Present
Psychologist/ASD Specialist PI: Suma Jacob, MD. PhD
The primary objectives of this study are to evaluate the efficacy of 12-week treatment with RO5285119 compared with placebo in treating social communication deficits in individuals with ASD as measured by the social responsiveness scale (SRS-2) and to evaluate the safety and tolerability of 12-week treatment with RO5285119 in individuals with ASD. Co-PI Rebekah Hudock. More at: http://www.roche-trials.com/trialDetailsGet.action?studyNumber=BP28420
Core Function(s):
Training Trainees, Performing Research or Evaluation, Developing & Disseminating Information
Target Audience:
Family Members/Caregivers, Adults with Disabilities
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A